2. Approved Prostate Cancer Drugs Insight by Class
2.1 Chemotherapeutic Drugs
2.2 Hormonal Therapy
2.3 Immunotherapy
2.3.1 Cancer Vaccines
2.3.2 Immune Checkpoint Inhibitors
2.4 PARP Inhibitors
3. Novel Emerging Therapies in Prostate Cancer
3.1 Bi-Specific T-Cell Engagers (BiTE)
3.2 Small Molecule Prostate Cancer Drugs
3.3 Radioligand Therapy
3.4 Antibody Drug Conjugates
4. US Prostate Cancer Drugs: Generic & Biosimilar Landscape
4.1 Current Scenario & Price Differential
4.2 Reimbursement Scenario
5. Anti-Androgen Drugs for Prostate Cancer - US Market Availability, Dosage, Patent & Price Insight
5.1 Apalutamide (Erleada)
5.2 Xtandi (Enzalutamide)
5.3 Darolutamide (Nubeqa)
5.4 Abiraterone (Zytiga)
5.5 Bicalutamide (Casodex)
5.6 Nilutamide (Nilandron)
5.7 Flutamide
6. PARP Inhibitors for Prostate Cancer – US Market Availability, Dosage, Patent & Price Insight
6.1 Rucaparib (Rubraca)
6.2 Olaparib (Lynparza)
7. Radioactive Pharmaceutical Agents for Prostate Cancer - US Market Availability, Dosage & Price Insight
7.1 Radium 223 Dichloride (Xofigo)
7.2 Fluciclovine 18F (Axumin)
8. Mitotic Inhibitors for Prostate Cancer - US Market Availability, Dosage, Price & Patent Insight
8.1 Cabazitaxel (Jevtana)
8.2 Docetaxel (Taxotere)
9. Immunotherapeutics for Prostate Cancer - US Market Availability, Dosage & Price Insight
9.1 Provenge (Sipuleucel – T)
9.2 Capromab Pendetide (ProstaScint)
10. Gonadotropin Releasing Hormones Drugs for Prostate Cancer - US Market Availability, Dosage & Price Insight
10.1 Triptorelin (Trelstar)
10.2 Leuprolide
10.3 Goserelin (Zoladex)
10.4 Histrelin Acetate Subcutaneous Implant (Supprelin LA/Vantas)
10.5 Degarelix (Firmagon/Gonax)
11. Estrogens for Prostate Cancer - US Market Availability, Dosage & Price Insight
11.1 Estradiol
11.2 Conjugated Estrogen
12. Other Prostate Cancer Targeting Therapeutics - US Market Availability, Dosage & Price Insight
12.1 Estramustine (Emcyt)
12.2 Mitoxantrone (Novantrone)
12.3 Cyclophosphamide
12.4 Capecitabine (Xeloda)
12.5 Zoledronic Acid (Zometa/Reclast)
13. US - Prostate Cancer Drug Clinical Trials Overview
13.1 By Biomarket
13.2 By Drug Class
13.3 By Formulation
13.4 By Organization
13.5 By Patient Segment
13.6 By Phase
14. US - Prostate Cancer Drugs Clinical Pipeline By Company, Indication & Phase
14.1 Unknown
14.2 Research
14.3 Preclinical
14.4 Clinical
14.5 Phase-0
14.6 Phase-I
14.7 Phase-I/II
14.8 Phase-II
14.9 Phase-III
14.10 Preregistration
14.11 Registered
16. US Prostate Cancer Market Dynamics
16.1 Market Drivers
16.2 Market Challenges
18. Compititive Landscape
18.1 AbbVie
18.2 Accord Healthcare
18.3 Allergan
18.4 Amgen
18.5 Astellas Pharma
18.6 AstraZeneca plc
18.7 Bayer
18.8 Bristol Mayer Squibb
18.9 Clovis Oncology
18.10 Dendreon
18.11 Genentech
18.12 Jassen Pharmaceuticals
18.13 Merck
18.14 Mylan
18.15 Novartis AG
18.16 Pfizer
18.17 Roche
18.18 Sanofi
18.19 Sun Pharma
18.20 Teva Pharmaceuticals
List of Figures
Figure 1-1: US - Estimated Cases & Deaths from Prostate Cancer, 2020 &2040
Figure 1-2: US - Prostate Cancer Drug Market Opportunity (US$ Billion), 2020 - 2026
Figure 2-1: Hormonal Therpay Targets in Prostate Cancer
Figure 2-2: Provenge – Mechanism of Action
Figure 2-3: Provenge in Clinical Trials
Figure 2-4: Keytruda – Mode of Action
Figure 2-5: Immune Checkpoint Inhibitors in Clinical Trial
Figure 2-6: PARP Inhibitors- Mode of Action
Figure 4-1: Prostate Cancer – Cost of Treatment (US$)
Figure 4-2: Taxotere & Docetaxel – Cost of Intravenous Solution Per Unit (US$)
Figure 4-3: Zytiga & Abiraterone – Cost of Oral Tablet per unit (US$)
Figure 4-4: Lynpraza – Total Cost of Treatment & Reimbursement Cost (US$)
Figure 4-5: Lynpraza - In Pocket Cost & Out Pocket Cost (%)
Figure 5-1: Erleada – Aragon related Patent Issue & expiration Year
Figure 5-2: Erleada – University of California related Patent Issue & Expiration Year
Figure 5-3: Erleada – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), January’2021
Figure 5-4: Erleada – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), January’2021
Figure 5-5: Xtandi – FDA Approval Year by Indication
Figure 5-6: Xtandi – Patent Issue & Expiration Year
Figure 5-7: Xtandi – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), January’2021
Figure 5-8: Xtandi – Recommended & Reduced Dose for Prostate Cancer Treatment (mg per day), January’2021
Figure 5-9: Xtandi – Cost of Single Capsule & Daily Treatment Cost (US$), January’2021
Figure 5-10: Nubeqa – Aragon Related Patent Issue & Expiration Year
Figure 5-11: Nubeqa – Price for 120 Tablet Supply & Price per unit of Oral Tablet (US$), January’2021
Figure 5-12: Nubeqa – Price of Single Tablet & Daily Treatment Cost (US$), January’2021
Figure 5-13: Zytiga – FDA Approval by Indication
Figure 5-14: Zytiga – FDA approval & First generic Approval Year
Figure 5-15: Zytiga – Price for Supply of 120 tablets & Price Per Unit Tablet of 250mg (US$), January’2021
Figure 5-16: Zytiga – Price for Supply of 60 tablets & Price Per Unit Tablet of 500mg (US$), January’2021
Figure 5-17: Generic Abiraterone – Price for Supply of 30 Tablets & 120 tablets & Price Per Unit Tablet of 250mg (US$), January’2021
Figure 5-18: Abiraterone – Daily Treatment Cost Branded v/s Generic (US$), January’2021
Figure 5-19: Casodex – FDA Approval & Patent Expiration Year
Figure 5-20: Casodax – Price for 30 Tablets Supply & Price Per Unit Tablet (US$), January’2021
Figure 5-21: Generic Bicalutamide – Price for 30 Tablets Supply & Price Per Unit Tablet (US$), January’2021
Figure 5-22: Nilandrone – FDA Approval & First Generic Approval Year
Figure 5-23: Eloxatin – FDA Approval Year by Strength of Tablet
Figure 5-24: Nilandrone – Price for 30 Tablet Supply & Price Per Unit Tablet of 150mg (US$), January’2021
Figure 5-25: Nilandrone – Recommended Dose for Prostate Cancer Treatment (mg/day), January’2021
Figure 5-26: Flutamide – Price for 180 Capsule Supply & Price per Unit Capsule of 125mg (US$), January’2021
Figure 5-27: Flutamide – Daily & Monthly Treatment Cost of Prostate Cancer (US$), January’2021
Figure 6-1: Rubraca – FDA Approval Year by Indication
Figure 6-2: Rubraca – FDA Approval Year by Strength
Figure 6-3: Rubraca - Number of Patents by Assignee
Figure 6-4: Rubraca - Patents Expiration Year by Assignee
Figure 6-5: Rubraca – Price for a Supply of 60 Tablets & Price Per Unit Tablet (US$), January’2021
Figure 6-6: Rubraca – Recommended Initial & Reduced Dose (mg/twice daily)
Figure 6-7: US - Rubraca Global Sales Value (US$ Million), 2018 & 2019
Figure 6-8: US - Rubraca Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 6-9: US - Rubraca Quarterly Sales Value (US$ Million), Q1-Q3, 2020
Figure 6-10: Lynparza – FDA Approval Year by Indication
Figure 6-11: Lynparza - Number of Patent Issued by Assignee Name
Figure 6-12: Lynparza – Patent Expiration Year by Assignee
Figure 6-13: Lynparza – Price for 60 & 120 Tablet Supply & Price Per Unit Tablet (US$), Janauary’2021
Figure 6-14: Lynparza – Recommended Dose & Dose after Reduction (mg/day)
Figure 6-15: US - Lynparza Annual Sales Value (US$ Million), 2017 - 2019
Figure 6-16: Lynparza - Annual Sales Value by Region (US$ Million), 2019
Figure 6-17: Lynparza – Annual Sales Value by Region (%), 2019
Figure 6-18: US - Lynparza Quarterly Sales Value (US$ Million), 2019
Figure 6-19: US - Lynparza Quarterly Sales Value (US$ Million), Q1-Q3, 2020
Figure 7-1: Xofigo – Patent Issue & Expiration Year
Figure 7-2: Xofigo – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 7-3: Xofigo – Cost of Single Treatment Cycle & Full Treatment (Weeks)
Figure 7-4: Axumin – Number of Patents by Assignee
Figure 7-5: Axumin – Patent Expiration Year by Assignee
Figure 8-1: Jevtana – Patent Issue & Expiration Year
Figure 8-2: Jevtana – Price for 1.5ml Supply & Price per unit of Intravenous Solution (US$), January’2021
Figure 8-3: Jevtana – Recommended & Incremented Dose of Jevtana for Prostate Cancer (mg/m2/3 weeks)
Figure 8-4: Taxotere – FDA Approval year by Strength
Figure 8-5: Taxotere – First Generic Approval year by Strength
Figure 8-6: Docetaxel – FDA Approval year by Companies
Figure 8-7: Taxotere – Price for 4ml Supply & Price per ml of 20mg/ml Intravenous Solution (US$, January’2021
Figure 8-8: Docetaxel – Average Price for 2ml, 8ml & 16ml Supply 10mg/ml Intravenous Solution (US$, January’2021
Figure 8-9: Docetaxel – Average Price for 1ml, 4ml, 8ml & 10ml Supply 20mg/ml Intravenous Solution (US$, January’2021
Figure 8-10: Docetaxel – Minimum & Maximum Recommended Dose (mg/m2/3 weeks)
Figure 9-1: Provenge – Price for 250 ml Supply & Price per ml of Intravenous Suspension (US$), January’2021
Figure 9-2: Provenge – Cost of Single Treatment Cycle & Cost of Full Treatment (US$), January’2021
Figure 10-1: Trelstar – FDA Approval Year by Dose Strength of Injection
Figure 10-2: Trelstar – Patent Issue & Expiration Year
Figure 10-3: Trelstar – Price for Various Supplies of Intravenous Powder (US$), January’2021
Figure 10-4: Trelstar – Recommended dose by Duration of Treatment Cycle (mg)
Figure 10-5: Leuprolide – FDA approval Year by Brand Name
Figure 10-6: Lupron Depot – Patent Issue & Expiration Year
Figure 10-7: Eligard – Cost of Various Supplies of Subcutaneous Powder for Injection (US$), January’2021
Figure 10-8: Lupron – Cost of Various Supplies of Intramuscular Kit (US$), January’2021
Figure 10-9: Lupron – Cost of Various Supplies of Intramuscular Powder for Injection (US$), January’2021
Figure 10-10: Lutrate – Cost of Various Supplies of Intramuscular Powder for Injection (US$/GBP), January’2021
Figure 10-11: Generic Leuprolide – Average Single Day, Monthly & Annual Treatment Cost of Prostate Cancer (US$), January’2021
Figure 10-12: Leuprolide – Average Annual Treatment Cost Comparison of Branded v/s Generic (US$), January’2021
Figure 10-13: Zoladex – FDA Approval Year by Strength of Implant
Figure 10-14: Zoladex – Patent Issue & Expiration Year
Figure 10-15: Zoladex – Price for Single 3.6mg & 10.8mg Implant (US$), January’2021
Figure 10-16: Zoladex – Recommended dose by Duration of Treatment Cycle (mg)
Figure 10-17: Histrelin – FDA approval Year by Brand Name
Figure 10-18: Supprelin LA – FDA Approval Year by Brand Name
Figure 10-19: Histrelin – Price for Single 50mg Implant by Brand Name (US$), January’2021
Figure 10-20: Degarelix – FDA & PMDA Approval Year
Figure 10-21: Firmagon – Patent Issue & Expiration Year
Figure 10-22: Firmagon – Price for Single 80mg & 120mg Powder for Injection (US$), January’2021
Figure 10-23: Degarelix – Recommended Initial Dose & Maintenance Dose (mg/4weeks)
Figure 11-1: Estrace – Price for 100 Tablets Supply & Price Per Unit Tablet of 0.5mg & 1mg Dose (US$), January’2021
Figure 11-2: Estrace – Price for 100 Tablets Supply & Price Per Unit Tablet of 2mg Dose (US$), January’2021
Figure 11-3: Delestrogen – Price for 5ml Supply & Price per ml of 10mg/ml Intramuscular Solution (US$), January’2021
Figure 11-4: Delestrogen – Price for 5ml Supply & Price per ml of 20mg/ml Intramuscular Solution (US$), January’2021
Figure 11-5: Delestrogen – Price for 5ml Supply & Price per ml of 40mg/ml Intramuscular Solution (US$), January’2021
Figure 11-6: Estradiol Tablet – Price for 100 Tablets Supply & 30 Tablets of 0.5mg Dose (US$), January’2021
Figure 11-7: Estradiol Tablet – Price for 100 Tablets Supply & 30 Tablets of 1mg Dose (US$), January’2021
Figure 11-8: Estradiol Tablet – Price for 100 Tablets Supply & 30 Tablets of 0.5mg Dose (US$), January’2021
Figure 11-9: Estradiol Valerate – Price for 5ml Supply & Price per ml of 20mg/ml Intramuscular Solution (US$), January’2021
Figure 11-10: Estradiol Valerate– Price for 5ml Supply & Price per ml of 40mg/ml Intramuscular Solution (US$), January’2021
Figure 11-11: Estradiol – Minimum & Maximum Oral Dose (mg/day), January’2021
Figure 11-12: Premarin – Price for 100 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), January’2021
Figure 11-13: Premarin – Price for 1000 Tablets Supply & Price Per Unit Tablet of Various Dose Regimens (US$), January’2021
Figure 11-14: Premarin – Minimum & Maximum Oral Dose (mg/day), January’2021
Figure 12-1: Emcyt – Price for 100 Capsules Supply & Price per unit Capsule of 140mg Dose (US$), January’2021
Figure 12-2: Emcyt – Minimum & Maximum Daily Dose (mg/Kg/day)
Figure 12-3: Mitoxantrone – Price for 10 ml Supply & Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021
Figure 12-4: Mitoxantrone – Price for 12.5 ml Supply & Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021
Figure 12-5: Mitoxantrone – Price for 15 ml Supply & Price per unit ml of 2mg/ml Intravenous Solution (US$), January’2021
Figure 12-6: Mitoxantrone – Minimum & Maximum Dose (mg/m2)
Figure 12-7: Cyclophosphamide – Price for various Supplies of intravenous Powder for Injection (US$), January’2021
Figure 12-8: Cyclophosphamide – Price for various Supplies of 200mg/ml intravenous Solution for Injection (US$), January’2021
Figure 12-9: Cyclophosphamide – Price for 100 Capsule Supply of 25mg & 50mg Dose (US$), January’2021
Figure 12-10: Cyclophosphamide – Minimum & Maximum Dose as Single Agent (mg/Kg), January’2021
Figure 12-11: Xeloda – FDA Approval Year & First Generic Approval Year
Figure 12-12: Capecitabine – Price for 60 Tablet Supply & Price per unit of 150mg Branded & Generic tablet (US$), January’2021
Figure 12-13: Xeloda – Price for 120 Tablet Supply & Price per unit of 500mg tablet (US$), January’2021
Figure 12-14: Capecitabine – Price for 120 Tablet Supply & Price per unit of 500mg tablet (US$), January’2021
Figure 12-15: Capecitabine – Duration of Single Treatment Cycle & Full Treatment (Weeks)
Figure 12-16: Zometa – FDA Approval & First Generic Approval Year
Figure 12-17: Reclast – FDA Approval & First Generic Approval Year
Figure 12-18: Zometa – Price for 5ml Supply & Price per ml of Intravenous Solution (US$), January’2021
Figure 12-19: Reclast – Price for 10ml Supply & Price per ml of Intravenous Solution (US$), January’2021
Figure 12-20: Generic Zoledronic Acid – Price for 5ml and 200ml Supply of 4mg/ml Intravenous Solution (US$), January’2021
Figure 12-21: Generic Zoledronic Acid – Price for 100ml & Price per ml of 4mg/100ml Intravenous Solution (US$), January’2021
Figure 12-22: Generic Zoledronic Acid – Price for 100ml & Price per ml of 5mg/100ml Intravenous Solution (US$), January’2021
Figure 13-1: US - Number of Prostate Cancer Drugs in Clinical Trials by Biomarker, 2021 till 2026
Figure 13-2: US - Number of Protate Cancer Drugs in Clinical Trials by Drug Class, 2021 till 2026
Figure 13-3: US - Number of Prostate Cancer Drugs in Clinical Trials by Formulation, 2021 till 2026
Figure 13-4: US - Number of Prostate Cancer Drugs in Clinical Trials by Organization, 2021 till 2026
Figure 13-5: US - Number of Prostate Cancer Drugs in Clinical Trials by Patient Segment, 2021 till 2026
Figure 13-6: US - Number of Prostate Cancer Drugs in Clinical Trials by Phase, 2021 till 2026
